President Trump to Announce Nationwide Medicaid Drug Pricing Model

Shreveport Texarkana, LA, September 18, 2026 —

Washington D.C. – President Donald Trump is expected to announce a significant initiative aimed at reducing prescription drug costs for Medicaid recipients across the United States. According to details emerging, the announcement will involve a plan for all 50 U.S. states to participate in a new Medicaid drug pricing model.

This proposed model is designed with the primary objective of lowering the net price of specific prescription drugs. The target pricing is intended to align with the costs paid for these medications in a selection of other developed countries. The initiative seeks to bring U.S. drug prices more in line with international benchmarks, a move that proponents argue could lead to substantial savings for both the government and consumers.

The scope of the announcement indicates a nationwide implementation, with all 50 states being brought into this framework. The exact timeline for this announcement or the subsequent rollout of the pricing model has not been specified. Further details regarding which drugs will be included in the program, the specific countries used as benchmarks for pricing, and the mechanisms for implementing these lower prices are also anticipated. The nature of the agreement for states to join the model, whether voluntary or mandated, remains to be elaborated upon.

This effort by the Trump administration represents a continuation of its focus on addressing the high cost of prescription drugs, a key issue during its term. The administration has previously explored various strategies to negotiate drug prices and increase transparency in the pharmaceutical market. The participation of all 50 states suggests a broad, federal-level push to standardize and reduce drug expenditures within the Medicaid program.

Story summarized from the original created by FATIMA HUSSEIN, Associated Press on www.ktalnews.com, see more information here.

Media gallery